

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **TATA Health International Holdings Limited**

### **TATA 健康國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1255)**

#### **ANNOUNCEMENT CHANGE OF AUDITOR**

This announcement is made by TATA Health International Holdings Limited (the “**Company**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

#### **RESIGNATION OF AUDITOR**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that Deloitte Touche Tohmatsu (“**Deloitte**”), after taking into account many factors including professional risk associated with audit, the level of audit fee and the available internal resources in the light of current work flows, has resigned as the auditor of the Company with effect from 30 September 2021 as the Company could not reach a consensus with Deloitte on the audit fee for the financial year ending 31 December 2021.

Deloitte has confirmed that, there are no matters relating to its resignation which need to be brought to the attention of the shareholders or creditors of the Company. Both the Board and the audit committee (the “**Audit Committee**”) of the Company confirm that there is no other disagreement between the Company and Deloitte, except for the audit fee for the financial year ending 31 December 2021, and there are no other matters in respect of the change of auditor which need to be brought to the attention of the shareholders or creditors of the Company.

The Board confirms that Deloitte has not commenced any audit work on the financial statements of the Company and its subsidiaries for the financial year ending 31 December 2021. It is therefore expected that the change of auditor will not have any material impact on the annual audit work of the Company and its subsidiaries for the financial year ending 31 December 2021.

## **APPOINTMENT OF NEW AUDITOR**

The Board further announces that, with the recommendation of the Audit Committee, HLB Hodgson Impey Cheng Limited has been appointed as the auditor of the Company with effect from 30 September 2021 to fill the casual vacancy following the resignation of Deloitte and to hold office until the conclusion of the next annual general meeting of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Deloitte for its services rendered to the Company over the past years.

By order of the Board  
**TATA Health International Holdings Limited**  
**Yang Jun**  
*Chairman*

Hong Kong, 30 September 2021

*As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Yang Jun and Mr. Lai Wenjing; four non-executive Directors, namely, Mr. Lin Zheming, Mr. Lin Jun, Mr. Chu Chun Ho, Dominic and Mr. Chen Anhua and three independent non-executive Directors, namely, Mr. Xie Rongxing, Prof. Yan Haifeng and Ms. Tan Yuying.*